Quarterly ResultMay 6, 2026, 07:56 AM
Bioventus Q1 Net Sales $132.1M; Net Income $3.9M; Repays $22M Debt
AI Summary
Bioventus Inc. reported strong financial results for the first quarter ended March 28, 2026, with net sales increasing by 6.6% to $132.1 million and a significant turnaround to net income of $3.9 million, compared to a net loss in the prior year. The company also made a discretionary prepayment of $22.0 million on its 2025 Term Loan, demonstrating improved financial management. These results follow the divestiture of its Advanced Rehabilitation Business in late 2024, allowing for a focus on core operations.
Key Highlights
- Net sales rose 6.6% to $132.1 million in Q1 2026 from $123.9 million in Q1 2025.
- Net income was $3.9 million in Q1 2026, reversing a $3.3 million net loss in Q1 2025.
- Diluted EPS improved to $0.04 in Q1 2026 from $(0.04) in Q1 2025.
- Operating income increased 72.8% to $8.4 million in Q1 2026.
- Net cash from operating activities was $8.9 million, up from $(19.3) million year-over-year.
- Company made a $22.0 million discretionary prepayment on its 2025 Term Loan.
- Interest expense, net, decreased 42.4% to $4.3 million in Q1 2026.
- Bioventus was in compliance with all 2025 Credit Agreement financial covenants.
Price Impact
More from BVS